Cancer Family
Uveal Melanocytic Neoplasm
CI-CAN-00000381Explore in graph →
Non-malignant59 active trials1 approved drugs17 evidence items
- NCIt
- C205057
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000381Explore in graph →
Clinical trials
232 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05907954 | (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma | active not recruiting | Phase 2 | 160 | IDEAYA BiosciencesINDUSTRY | 7 | Mar 16, 2026 | clinicaltrials |
| NCT07364474 | Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver | recruiting | N/A | 10 | Massachusetts General HospitalOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT04792463 |
| Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome |
| recruiting |
| — |
| 500 |
| Mohamed Abdel-RahmanOTHER |
| 1 |
| Mar 9, 2026 |
| clinicaltrials |
| NCT06627244 | Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma | recruiting | Phase 2 | 30 | University of MiamiOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT07421739 | Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects | recruiting | — | 15 | Aura BiosciencesINDUSTRY | 1 | Feb 19, 2026 | clinicaltrials |
| NCT02517736 | Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (Nexavar®) in Adult Patients With Uveal Melanoma and Metastatic Dissemination(O-Mel-Sora) | completed | Phase 2 | 32 | University Hospital, CaenOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT05987332 | IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma | active not recruiting | Phase 2 / Phase 3 | 420 | IDEAYA BiosciencesINDUSTRY | 13 | Feb 17, 2026 | clinicaltrials |
| NCT04552223 | Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma | completed | Phase 2 | 27 | Jose Lutzky, MDOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT04645680 | Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy(DIET) | active not recruiting | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT01983748 | Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma | completed | Phase 3 | 200 | University Hospital ErlangenOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT03865212 | Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma | terminated | Phase 1 | 12 | Mayo ClinicOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06717126 | A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma(OCULE-01) | active not recruiting | Phase 2 | 85 | iOncturaINDUSTRY | 3 | Jan 16, 2026 | clinicaltrials |
| NCT03746431 | A Phase 1 Study of [225Ac]-FPI-1434 Injection | terminated | Phase 1 | 78 | Fusion Pharmaceuticals Inc.INDUSTRY | 3 | Jan 7, 2026 | clinicaltrials |
| NCT06022029 | A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.(ON-5001) | recruiting | Phase 1 | 168 | OncoNano Medicine, Inc.INDUSTRY | 2 | Dec 24, 2025 | clinicaltrials |
| NCT04082962 | Dexamethasone Implant for Retinal Detachment in Uveal Melanoma | completed | Phase 1 | 10 | Ivana K. KimOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT06121180 | Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma | recruiting | Phase 2 | 32 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT07136181 | Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma(NBM-BMX-UM) | recruiting | Phase 1 / Phase 2 | 36 | Novelwise Pharmaceutical CorporationINDUSTRY | 1 | Nov 28, 2025 | clinicaltrials |
| NCT01334008 | Study of Circulating Tumoral DNA in Metastatic Choroidal Melanoma | completed | N/A | 40 | Institut CurieOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06784648 | Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma | active not recruiting | Phase 1 / Phase 2 | 35 | BioInvent International ABINDUSTRY | 3 | Nov 19, 2025 | clinicaltrials |
| NCT05812027 | A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors | active not recruiting | — | 1,150 | TScan Therapeutics, Inc.INDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT01473004 | SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver | completed | Phase 2 | 48 | Thomas Jefferson UniversityOTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT04935229 | Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma | terminated | Phase 1 | 67 | TriSalus Life Sciences, Inc.INDUSTRY | 1 | Oct 22, 2025 | clinicaltrials |
| NCT03712904 | Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma | terminated | Phase 2 | 3 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Sep 24, 2025 | clinicaltrials |
| NCT06805825 | A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit | recruiting | Phase 1 | 67 | Novelty Nobility, Inc.INDUSTRY | 1 | Sep 23, 2025 | clinicaltrials |
| NCT04812470 | Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases(HAITILS) | completed | Phase 1 | 8 | Vastra Gotaland RegionOTHER_GOV | 1 | Sep 22, 2025 | clinicaltrials |
| NCT02849145 | Evaluation Interest of the Circulating Tumor DNA Dosage in Patient With Hepatic Metastatic Uveal Melanoma Candidate to Complete Resection (ct DNA R0)(ctDNA R0) | completed | N/A | 60 | Institut CurieOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT04118062 | Communicating With Patients on Cancer Resistance to Treatment: the Development of a Communication Tool. (HECTOR) | completed | N/A | 128 | Institut CurieOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT05893654 | Melphalan Chemoreduction for Ocular Melanoma(MELCOM) | enrolling by invitation | Phase 1 / Phase 2 | 10 | Hospital das Clínicas de Ribeirão PretoOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT04283890 | PHP and Immunotherapy in Metastasized UM(CHOPIN) | active not recruiting | Phase 1 / Phase 2 | 83 | Leiden University Medical CenterOTHER | 1 | Sep 9, 2025 | clinicaltrials |
| NCT04728113 | Early Integration of Supportive Care for Metastatic Uveal Melanoma Patients (EarlyTogether)(EARLY TOGETHER) | completed | N/A | 162 | Institut CurieOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT04424719 | Follow-up of Patients With Uveal Melanoma Adapted to the Risk of Relapse (SALOME)(SALOME) | recruiting | N/A | 700 | Institut CurieOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT05004025 | Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma | completed | Phase 1 | 10 | HonorHealth Research InstituteOTHER | 1 | Aug 15, 2025 | clinicaltrials |
| NCT03964298 | Study of the Activity of PD-1 Inhibitors in Metastatic Uveal Melanoma(imMUno) | completed | — | 100 | Institut CurieOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT02874040 | Endoresection of the Tumor Scar or Transpupillary Thermotherapy for the Treatment of Large Uveal Melanomas (Endoresection-Laser) | completed | N/A | 87 | Institut CurieOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT03611868 | A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 230 | Ascentage Pharma Group Inc.INDUSTRY | 2 | Aug 7, 2025 | clinicaltrials |
| NCT05315258 | Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma(TebeMRD) | active not recruiting | Phase 2 | 850 | University of OxfordOTHER | 1 | Jul 17, 2025 | clinicaltrials |
| NCT04720417 | Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma | terminated | Phase 2 | 13 | Thomas Jefferson UniversityOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT07063875 | Adding IL-2 to Tebentafusp to Eradicate Cancer Progression(SILVER) | recruiting | Phase 1 / Phase 2 | 8 | St Vincent's Hospital, SydneyOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT00661622 | Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF | completed | Phase 2 | 53 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT03922880 | Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma | completed | Phase 1 | 9 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT05502900 | Adjuvant Melatonin for Uveal Melanoma(AMUM) | recruiting | Phase 3 | 100 | Gustav StalhammarOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT04463368 | Isolated Hepatic Perfusion in Combination With Ipilimumab and Nivolumab in Patients With Uveal Melanoma Metastases(SCANDIUM II) | completed | Phase 1 | 18 | Vastra Gotaland RegionOTHER_GOV | 1 | Mar 28, 2025 | clinicaltrials |
| NCT04802876 | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors(ACROPOLI) | active not recruiting | Phase 2 | 184 | SOLTI Breast Cancer Research GroupOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT05576077 | A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors(STARLING) | terminated | Phase 1 | 31 | Turnstone Biologics, Corp.INDUSTRY | 2 | Mar 10, 2025 | clinicaltrials |
| NCT06863870 | Assessment of Circulating Tumor Cells and microRNAs in Patients With Metastatic Non-cutaneous Melanoma | active not recruiting | — | 35 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT04417530 | Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma | completed | Phase 2 | 22 | Aura BiosciencesINDUSTRY | 1 | Mar 3, 2025 | clinicaltrials |
| NCT01338389 | Influence of Oral Treatment With Citicoline for the Prevention of Radiation Optic Neuropathy in Patients Treated for Uveal Melanomas With Proton Beam Therapy | completed | N/A | 21 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT02936388 | Transarterial Radioembolisation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma Liver Metastasis(SirTac) | completed | Phase 2 | 108 | Charite University, Berlin, GermanyOTHER | 1 | Jan 24, 2025 | clinicaltrials |
| NCT06519266 | PHP in Combination With IPI1/NIVO3 Compared to IPI3/NIVO1 Only in Patients With Uveal Melanoma Liver Metastases(SCANDIUM-III) | recruiting | Phase 3 | 40 | Vastra Gotaland RegionOTHER_GOV | 1 | Nov 25, 2024 | clinicaltrials |
| NCT05169957 | Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I) | completed | Phase 1 | 2 | University of Michigan Rogel Cancer CenterOTHER | 1 | Nov 5, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Mar 16, 2026source: clinicaltrials